Focusing on the treatment of diabetic macular edema
10.3760/cma.j.issn.1005-1015.2016.02.002
- VernacularTitle:重视对糖尿病黄斑水肿的治疗
- Author:
Xun XU
;
Ying ZHENG
- Publication Type:Journal Article
- Keywords:
Macular edema/therapy;
Macular edema/drug therapy;
Laser coagulation;
Angiogenesis inhibitors/therapeutic use;
Antibodies,monoclonal/therapeutic use;
Diabetes complications;
Editorial
- From:
Chinese Journal of Ocular Fundus Diseases
2016;32(2):119-121
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema (DME) is thickening retina with two disc diameter,which is the leading cause of blindness in diabetic retinopathy patients.The initial studies demonstrated that laser treatment of DME prevented further visual deterioration but did not improve visual acuity.Although glucocorticoid slow-release system can extend the time of effective drug concentration,to help glucocorticoid better carry out its biological effect,further studies are needed to warrant their safety due to increasing intraocular pressure and cataract progression.Novel studies identifying the presence of vascular endothelial growth factor (VEGF) in the eye with DME allowed for the development of an alternative anti-VEGF therapy,which revolutionized the management of DME by not only preventing vision loss,but also improving overall vision.Anti-VEGF therapy is becoming the first-line treatment of DME.However,present treatment modalities including anti-VEGF for DME had limitations,which build on the current understanding of DME pathogenesis.Further in-depth study of the development and outcome of DME is needed to optimize the therapeutic schemes,based on objective and scientific observation of treatment response.Finally we need to fully utilize the public health services and clinical management resources for diabetic patients,to prevent the visual impairment of DME before its occurrence.
